Oxford Ledge
Search
Market prices for AEON are shown to signed-in users (sign in). This public page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.
AEON Biopharma, Inc. (AMEX: AEON) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-21 06:32 UTC.
AEON Biopharma is a biopharmaceutical company developing ABP-450, a botulinum toxin complex designed as a biosimilar to the branded drug Botox for therapeutic medical indications. The company holds exclusive development and commercialization rights for ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories, and is pursuing approval through the FDA's biosimilar pathway. ABP-450 is already approved for aesthetic use in the United States under the brand name Jeuveau and is marketed in multiple international markets.
Summarized from AEON Biopharma, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗
Charts, 10-year financials, peer comparison, screening and portfolio tracking for AEON and 5,000+ tickers.
Create a free account — keep AEONGET /api/data?ticker=AEON
This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt